Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Analysts Review
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, April 24, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Bristol-Myers Squibb Company (NYSE: BMY) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1516-100free.
Johnson & Johnson Analyst Notes
On April 15, 2014, Johnson & Johnson announced Q1 2014 financial results. The Company announced sales of $18.1 billion, up 3.5% YoY. Net earnings were $4.7 billion, or $1.64 per diluted share, compared to $3.5 billion, or $1.22 per diluted share, in Q1 2013. "Johnson & Johnson delivered strong first-quarter results driven by successful new product launches and the continued growth of key products," said Alex Gorsky, Chairman and CEO of Johnson & Johnson. "Our talented colleagues around the world continue to bring meaningful innovations to patients and customers, addressing significant unmet needs. We also advanced our near-term priorities and long-term growth drivers, positioning us well to deliver sustainable results." The Company stated that it increased its earnings guidance for full-year 2014 and expects it to be in the range of $5.80 to $5.90 per share. The full analyst notes on Johnson & Johnson are available to download free of charge at:
Merck & Co., Inc. Analyst Notes
On April 17, 2014, Merck & Co., Inc. (Merck) announced that the U.S. Food and Drug Administration (FDA) has approved RAGWITEK (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use. The Company added that RAGWITEK is approved for use in adults 18 through 65 years of age, and is not indicated for the immediate relief of allergic symptoms. "The FDA approval of RAGWITEK brings an important new option for allergy specialists treating adults with allergic rhinitis with or without conjunctivitis caused by short ragweed pollen," said Dr. Sean Curtis, Vice President of Respiratory and Immunology at Merck Research Laboratories. "Merck is proud to add this second sublingual allergen immunotherapy tablet to our respiratory portfolio." The full analyst notes on Merck are available to download free of charge at:
Teva Pharmaceutical Industries Ltd Analyst Notes
On April 19, 2014, Teva Pharmaceutical Industries Ltd (Teva) reported that while the Chief Justice of the United States found that the Company had demonstrated "a fair prospect of success on the merits" in its appeal of a decision from the US Court of Appeals for the Federal Circuit that invalidated the claim of US Patent 5,800,808 (the 808 patent), he denied Teva's application to stay the Federal Circuit's decision due to the potential for the Company to recover patent infringement damages. Teva noted that the 808 patent is expected to expire on September 1, 2015 and claims a process for manufacturing the active ingredient of COPAXONE 20mg/mL, which is the Company's relapsing-remitting multiple sclerosis (RRMS) product. Further, the Company stated that it intends to continue pursuing its appeal in the Supreme Court and defending its intellectual property for COPAXONE. The full analyst notes on Teva are available to download free of charge at:
Bristol-Myers Squibb Company Analyst Notes
On April 14, 2014, Bristol-Myers Squibb Company (Bristol-Myers Squibb) announced that it has submitted a new drug application (NDA) on April 4, 2014 to the U.S. Food and Drug Administration (FDA) for a fixed-dose combination of atazanavir sulphate, a protease inhibitor marketed as Reyataz, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the blood and make them more effective. Bristol-Myers Squibb stated that if approved, the Company expects atazanavir sulphate and cobicistat to offer patients living with HIV-1, a single tablet that eliminates the need to take a boosting agent in a separate tablet. The full analyst notes on Bristol-Myers Squibb are available to download free of charge at:
AbbVie Inc. Analyst Notes
On April 15, 2014, AbbVie Inc. (AbbVie) announced the initiation of a global Phase III trial that evaluates the safety and efficacy of its investigational compound, veliparib (ABT-888), in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). According to the Company, this randomized, placebo-controlled, double-blind, multicenter, Phase III trial will compare patients receiving either the standard chemotherapies of carboplatin and paclitaxel with the addition of veliparib, versus patients receiving carboplatin and paclitaxel with the addition of placebo. AbbVie added that the trial will enrol approximately 900 patients. "This Phase III trial is an important step in the development of veliparib and in potentially providing patients with squamous non-small cell lung cancer with a new treatment option," said Scott Brun M.D., Vice President of Pharmaceutical Development at AbbVie. The full analyst notes on AbbVie are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.